This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Sector ETFs & Stocks Likely to Benefit Despite Soft Jobs Data
by Sanghamitra Saha
The U.S. economy added 175, 000 jobs in April, well below Wall Street expectations of 240, 000.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tenet Healthcare Corporation (THC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Strong Picks to Ride the Wave of Relative Price Strength
by Nilanjan Choudhury
SKYW, POWL, MTX, COCO and THC are five stocks with explosive relative price strength.
Best Momentum Stocks to Buy for May 3rd
by Zacks Equity Research
NFLX, MS and THC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 3, 2023.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Despite Fast-paced Momentum, Tenet (THC) Is Still a Bargain Stock
by Zacks Equity Research
Tenet (THC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
New Strong Buy Stocks for May 3rd
by Zacks Equity Research
MS, NFLX, SIGA, THC and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on May 3, 2023.
Best Value Stocks to Buy for May 3rd
by Zacks Equity Research
SIGA, TMHC and THC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 3, 2023.
Tenet Healthcare (THC) Beats on Q1 Earnings, Ups '24 EPS View
by Zacks Equity Research
Tenet Healthcare's (THC) Q1 results reflect strength in admissions and improved pricing yield. It expects an adjusted EPS of $8.37-$9.41 for 2024, higher than the earlier mentioned $5.76-$6.90.
Tenet (THC) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Tenet (THC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tenet Healthcare (THC) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of 122.07% and 4.42%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Sustained Product Demand Likely to Aid BD's (BDX) Q2 Earnings
by Zacks Equity Research
Continued solid uptake of BD's (BDX) products is expected to have driven fiscal second-quarter revenues.
Factors Setting the Tone for Ecolab's (ECL) Q1 Earnings
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued segmental strength.
HCA Healthcare (HCA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 6.99% and 2.93%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare
by Zacks Equity Research
Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare are part of the Zacks top Analyst Blog.
Stay Ahead With 4 Healthcare Stocks Poised for Q1 Earnings Beat
by Kaibalya Pravo Dey
Growing patient volumes, advancements in technology, admissions, premium rate hikes and other factors are likely to have benefited healthcare players during Q1. Companies like CI, HCA, AVTR and THC can outperform.
Universal Health Services (UHS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 17.83% and 1.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Tenet (THC) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Tenet (THC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Tenet Healthcare (THC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Tenet Healthcare (THC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Tenet Healthcare (THC) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Tenet Healthcare (THC) stood at $102.18, denoting a +1.46% change from the preceding trading day.
Tenet Healthcare (THC) Soars 76% in a Year: What Lies Ahead?
by Zacks Equity Research
Tenet Healthcare (THC) remains well-poised for growth on increased admissions and surgeries in the Hospital segment, acquisitions, debt repayment efforts and solid operating cash flows.
Should You Invest in Tenet (THC) Based on Bullish Wall Street Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Tenet (THC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Tenet (THC) Divests Six Hospitals, Sustains Divestiture Spree
by Zacks Equity Research
Tenet Healthcare (THC) completes the sale of six California hospitals, four to UCI Health and two to Adventist Health, to refine the portfolio and reduce debt burden.